Previous 10 | Next 10 |
The following slide deck was published by Intercept Pharmaceuticals, Inc. in conjunction with their 2021 Q2 earnings call. For further details see: Intercept Pharmaceuticals, Inc. 2021 Q2 - Results - Earnings Call Presentation
Intercept Pharmaceuticals (NASDAQ:ICPT) shares rise more than 3% premarket after the company posted second-quarter results that beat Wall Street estimates, helped by the strength in its Ocaliva franchise. The company's liver disease therapy Ocaliva brought in $96...
Intercept Pharma (NASDAQ:ICPT): Q2 GAAP EPS of -$0.33 beats by $0.89. Revenue of $96.58M (+25.0% Y/Y) beats by $13.89M. Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operating expense guidance of $380 to $410 mil...
Worldwide Ocaliva ® net sales of $96.6 million, representing 25% growth over the prior year quarter Company reiterates 2021 financial guidance of Ocaliva net sales guidance of $325 million to $340 million and Non-GAAP adjusted operatin...
Shares of the small-cap biotech Intercept Pharmaceuticals (NASDAQ: ICPT) sank by a noteworthy 19% during the first six months of 2021, according to data from S&P Global Market Intelligence . The biotech's stock has slumped this year due mainly to the fallout from the U.S. Fo...
NEW YORK, July 19, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, will announce its second quarter 2021 financial result...
NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief ...
At the conclusion of the 2021 Russell indexes annual reconstitution, following notable healthcare stocks will join the Russell Microcap Index, effective June 28 after the U.S. market opens.Asensus Surgical (ASXC), Organovo Holdings (ONVO), Senseonics Holdings (SENS), Clovis Onc...
Intercept Pharmaceuticals (ICPT) announces the appointment of Michelle Berrey as President of Research & Development and Chief Medical Officer."Dr. Berrey brings a wealth of leadership experience in drug development and executive management to Intercept, and I am very pleased to...
NEW YORK, June 09, 2021 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the appointment of M. Michelle Berrey,...
News, Short Squeeze, Breakout and More Instantly...
Intercept Pharmaceuticals Inc. Company Name:
ICPT Stock Symbol:
NASDAQ Market:
Intercept Pharmaceuticals Inc. Website:
MORRISTOWN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a biopharmaceutical company and wholly owned subsidiary of Alfasigma S.p.A. focused on the development and commercialization of novel therapeutics to treat rare and serious liver diseases, today announced five abs...
sNDA intended to satisfy post-marketing requirements to confirm a clinical benefit in patients with PBC Precedent-setting submission includes data from post-marketing studies COBALT and Study 401 as well as real-world evidence from a claims database and patient registries FDA has assign...
Data from two Phase 2 studies in PBC show combination of OCA + bezafibrate achieved biochemical remission (normalization of ALP, total bilirubin, GGT, ALT and AST) in 40-44% of patients in the first 12 weeks OCA 5 or 5-10 mg + bezafibrate 400 mg cohorts in both studies showed a >60% ...